VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Managing the late consequences of CHD: What is the evidence for lipid management Prof Philip Barter The Heart Research Institute Sydney, Australia Slides.

Dr sajeer Senior Resident Dept. of Cardiology, MCH, Calicut

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

The overwhelming case for LDL-C lowering

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

4S: Scandinavian Simvastatin Survival Study

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:

Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

TNT: Study Design Treating to New Targets

HOPE: Heart Outcomes Prevention Evaluation study

Reduction in Total Cardiovascular Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the FOURIER Trial Sabina A. Murphy,

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

TNT: Baseline and final LDL cholesterol levels

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

This series of slides highlights a report based on a presentation at the Late-Breaking Trial Sessions of the 2005 American Heart Association Scientific.

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Potential mechanisms whereby statins may reduce the risk of stroke

ARISE Trial Aggressive Reduction of Inflammation Stops Events

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

FIELD: Primary outcome

Presentation transcript:

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study

VBWG IDEAL: Study design Objective: To compare intensive vs less-intensive lipid-lowering therapies Design: Prospective, randomized, open-label, blinded end-point evaluation ( PROBE) Population: N = 8888 with previous MI Treatment: Atorvastatin 80 mg, simvastatin mg/d Primary outcome: Coronary death, nonfatal MI, resuscitated cardiac arrest Secondary outcomes: Major CVD (primary event, stroke), CHD (primary event, coronary revascularization, hospitalization for UA), any CVD (any of the above, PAD, hospitalization for CHF), all-cause mortality Follow-up: Median 4.8 years Pedersen TR et al. JAMA. 2005;294: Incremental Decrease in End Points Through Aggressive Lipid Lowering

VBWG IDEAL: Reduction in primary endpoint Pedersen TR et al. JAMA. 2005;294: Cumulative hazard (%) Major coronary event* Time from randomization (years) No. at risk Simvastatin Atorvastatin Simvastatin Atorvastatin 11% RRR HR = 0.89 (95% CI, 0.78–1.01) P = 0.07 *Death from CAD, nonfatal MI, cardiac arrest with resuscitation Incremental Decrease in End Points Through Aggressive Lipid Lowering

VBWG IDEAL: Reduction in secondary endpoints Pedersen TR et al. JAMA. 2005;294: Cumulative hazard (%) Any coronary heart disease* Time from randomization (years) No. at risk Simvastatin Atorvastatin Any cardiovascular disease † Time from randomization (years) Simvastatin Atorvastatin Simvastatin Atorvastatin * Major coronary event, hospitalization for UA, coronary revascularizations † CHD endpoints, peripheral vascular disease, hospitalization for nonfatal CHF Incremental Decrease in End Points Through Aggressive Lipid Lowering 16% RRR HR = 0.84 (95% CI, 0.76–0.91) P < % RRR HR = 0.84 (95% CI, 0.78–0.91) P < 0.001

VBWG IDEAL: Summary High-dose atorvastatin vs usual-dose simvastatin in post-MI patients: Trend to benefit in primary outcome (11% RRR) Significant reductions in composite secondary outcomes (13% to 16%) No difference between groups in all-cause or CV mortality No difference between groups in serious adverse events – Incidence of liver enzyme elevation with atorvastatin was <1% and comparable with results of other trials 4 studies now support aggressive lipid lowering to reduce CV events in high-risk patients: IDEAL, PROVE IT-TIMI 22, A to Z, TNT Pedersen TR et al. JAMA. 2005;294: Cannon CP. JAMA. 2005;294: Incremental Decrease in End Points Through Aggressive Lipid Lowering